section name header

Table 180-2

Conditions, Diseases, and Medications That Contribute to Osteoporosis and Fractures

Lifestyle factors
Alcohol abuseHigh salt intakeFalling
Low calcium intakeInadequate physical activityExcessive thinness
Vitamin D insufficiencyImmobilizationPrior fractures
Excess vitamin ASmoking (active or passive)
Genetic factors
Cystic fibrosisHomocystinuriaOsteogenesis imperfecta

Ehlers-Danlos syndrome

Hypophosphatasia

Parental history of hip fracture

Gaucher's disease

Idiopathic hypercalciuria

Porphyria
Glycogen storage diseasesMarfan's syndromeRiley-Day syndrome
HemochromatosisMenkes' steely hair syndrome

Hypogonadal states

Androgen insensitivity

Hyperprolactinemia

Athletic amenorrhea

Anorexia nervosa and bulimia

Premature menopause

Panhypopituitarism

Turner's & Klinefelter's syndromes

Premature ovarian failure

Endocrine disorders
Adrenal insufficiencyCushing's syndromeCentral adiposity
Diabetes mellitus (types 1 and 2)HyperparathyroidismThyrotoxicosis
Gastrointestinal disorders

Celiac disease

Inflammatory bowel diseasePrimary biliary cirrhosis

Gastric bypass

Malabsorption

Gastrointestinal surgery

Pancreatic disease
Hematologic disorders

Multiple myeloma

Monoclonal gammopathies

Sickle cell disease

Hemophilia

Leukemia and lymphomas

Systemic mastocytosis

Thalassemia
Rheumatologic and autoimmune diseases
Ankylosing spondylitisLupusRheumatoid arthritis
Other rheumatic and autoimmune diseases
Central nervous system disorders
EpilepsyParkinson's diseaseStroke
Multiple sclerosisSpinal cord injury
Miscellaneous conditions and diseases

AIDS/HIV

Congestive heart failure

Posttransplant bone disease

Alcoholism

Depression

Sarcoidosis

Amyloidosis

End-stage renal disease

Weight loss

Chronic metabolic acidosis

Hypercalciuria

Chronic obstructive lung disease

Idiopathic scoliosis

Muscular dystrophy

Medications

Aluminum (in antacids)

Glucocorticoids (5 mg/d prednisone or equivalent for 3 months)

Tamoxifen (premenopausal use)

Anticoagulants (heparin)Gonadotropin-releasing hormone antagonists and agonistsThiazolidinediones (such as pioglitazone and rosiglitazone)

Anticonvulsants

Lithium

Thyroid hormones (in excess)

Aromatase inhibitors

Methotrexate

Parenteral nutrition

Barbiturates

Proton pump inhibitors

Cancer chemotherapeutic drugs

Selective serotonin reuptake inhibitors

Cyclosporine A and tacrolimus

Depo-medroxyprogesterone (premenopausal contraception)

Source: From the 2014 National Osteoporosis Foundation Clinician's Guide to the Prevention and Treatment of Osteoporosis. © National Osteoporosis Foundation.